The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.
The complaint alleges that NeuMoDx is willfully infringing on six BD-held patents, and demands injunctive relief, damages, and a jury trial.
The company reaffirmed its full fiscal year 2019 comparable, currency-neutral revenue guidance, and updated its adjusted diluted EPS guidance.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.
Beckman Coulter got regulatory clearance for three in vitro diagnostic products, including its DxH 520 hematology analyzer for low-volume clinical labs.
The system is used to automate sample preparation steps for assays that are run on BD's FACSLyric clinical flow cytometer.
The company reported growth across all three of its business segments and reaffirmed its full-year guidance.
Illumina said this week that the US Food and Drug Administration has granted breakthrough device designation for its pan-cancer assay, which is currently in development.
The firm also reaffirmed its previous guidance of 10 percent growth for fiscal 2019.